Checked.be
Active
BE 0588.990.037Private limited company (pre-2019)Open bankruptcy
EF Pharma
· 11 yrs active
Sector: Advertising & market research
(73300)
Conclusion
A bankruptcy procedure is open for EF Pharma according to publications in the Belgian State Gazette. The file additionally contains 2 judicial reorganisations. The 2020 annual accounts show negative equity (€-283k) and a net result of €-295k.
Based on the State Gazette, CBE and 3 annual accounts.
Key figures
| Equity | €-283k |
| Net result | €-295k |
| Staff (FTE) | 0.6 |
| Better than sector | 13% |
Snowflake analysis
34
/ 100
Fragile profile, watch health in particular.
Health
0
Profitability
100
Solvency
36
Growth
32
Stability
0
Bankruptcy probability (12 mo)
Bankruptcy opened
A bankruptcy procedure is already open, a probability score is no longer meaningful. See the insolvency timeline for the state of the procedure.
Risk Assessment
70 / 100
Severe riskComponents
· 2 judicial reorganisations (+20)
· Open bankruptcy (+50)
Trust signals
Open bankruptcy
Active bankruptcy procedure in the Belgisch Staatsblad. Claims are handled by the appointed curator.
Administrative Flags
No administrative flags
Health barometer
0
/ 100
Critical
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →Computed by Checked from NBB filings and Belgian State Gazette signals. Indicative, not credit advice.
Financial overview
Annual accounts filed on 28-09-2021 with the NBB · fiscal year 2020 · verkort
Sector comparison
Fiscal year 2020 · NACE 73, Advertising & market research · compared within the same schema type (abbreviated schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | -58.2% | 30.7% | |
| Net result | €-92k | €10k | |
| Equity | €-283k | €188k | |
| Gross operating margin | €-35k | €111k | |
| Employees (FTE) | 0.6 | 3.9 |
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
€-54k
-3.9%
far below sector median
€-295k
-46.1%
far below sector median
€-265k
-68.7%
far below sector median
€487k
+22.1%
-59% vs sector
€-283k
-49.1%
far below sector median
€-153k
+41.1%
far below sector median
1
+20.0%
-96% vs sector
€1k
+15.1%
-95% vs sector
€770k
+30.8%
+59% vs sector
€426k
-7.7%
-7% vs sector
€310k
+145.2%
18-20
0.64
+46.6%
-70% vs sector
0.42
+64.9%
-80% vs sector
-58.2%
-22.1%
far below sector median
-1.10
-64.5%
far below sector median
104.4%
-2.0%
+183% vs sector
-60.7%
-19.6%
far below sector median
Figures by fiscal year
| Fiscal year | 2020 |
|---|---|
| Revenue | - |
| EBITDA | €-54k |
| Net profit | €-295k |
| Cash flow | €-265k |
| Staff costs | - |
| Income taxes | €1k |
| Dividends | - |
| Total assets | €487k |
| Equity | €-283k |
| Debt | €770k |
| of which ≤ 1y | €426k |
| of which > 1y | €310k |
| Working capital | €-153k |
| Employees (FTE) | 0.6 |
Ratios (computed)
| 2020 | |
|---|---|
| Current ratio | 0.64 |
| Quick ratio | 0.42 |
| Working capital ratio | -31.5% |
| Solvency | -58.2% |
| Debt / equity | -1.10 |
| Long-term debt ratio | -1.10 |
| Interest coverage | - |
| Gross margin | - |
| Net margin | - |
| ROA | -60.7% |
| ROE | 104.4% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
Balance-sheet composition 2020
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2020 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €487k |
| Fixed assets | 21/28 | €213k |
| Tangible fixed assets | 22/27 | €171k |
| Financial fixed assets | 28 | €42k |
| Current assets | 29/58 | €273k |
| Stocks & contracts in progress | 3 | €93k |
| Amounts receivable within one year | 40/41 | €179k |
| Cash & bank | 54/58 | €262 |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €487k |
| Equity | 10/15 | €-283k |
| Accumulated profits (losses) | 14 | €-295k |
| Amounts payable | 17/49 | €770k |
| Amounts payable after one year | 17 | €310k |
| Amounts payable within one year | 42/48 | €426k |
| Trade debts payable within one year | 44 | €168k |
| Income statement | ||
| Gross operating margin | 9900 | €-35k |
| Operating result | 9901 | €-84k |
| Financial income | 75 | €1 |
| Financial charges | 65 | €7k |
| Result before taxes | 9903 | €-91k |
| Income taxes | 67/77 | €1k |
| Net result for the period | 9904 | €-92k |
| Result to be appropriated | 9905 | €-92k |
You're seeing the latest fiscal year only. Unlock 2 prior years (figures + ratios) with a paid plan.
See plans →
Ratios computed by Checked.
Directors & mandates
| Role | Name | Tenure | Source |
|---|---|---|---|
| Curator | THOMAS VANDENDRIES STEENWEG OP SINT JORIS
WINGE 21, 3200 AARSCHOT |
12-10-2021 → present | Belgian State Gazette |
Legal Structure
| NACE primary | Advertising & market research(73300) |
| Legal form | Private limited company (pre-2019)(015) |
| Incorporation | 29-01-2015 |
| Status | Active |
| Postal code | - |
| First BS signal | 21-06-2021 |
| Latest BS signal | 19-10-2021 |
Company structure, linked entities
Mandates
↔
1
of these mandate-holders are active on other cases, click any red card to open that KBO.
Establishment units
Par Isis
since 20152.298.550.503
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Real-estate footprint
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 23772B0101/00B000 | Flanders | 5,421 m² | 1 · 499 m² | - |
Methodology
via registered seat: 1
1 of 1 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
2021
19-10-2021
Bankruptcy
Opening
28-09-2021
NBB filing
Annual accounts filed
25-06-2021
Judicial reorganisation
Opening
21-06-2021
Judicial reorganisation
Opening
2020
29-10-2020
NBB filing
Annual accounts filed
2019
30-09-2019
NBB filing
Annual accounts filed
2018
23-08-2018
NBB filing
Annual accounts filed
2017
31-08-2017
NBB filing
Annual accounts filed
2016
26-08-2016
NBB filing
Annual accounts filed
Lifecycle & Insolvency Signals
19-10-2021
Bankruptcy
Opening
25-06-2021
Judicial reorganisation
Opening
21-06-2021
Judicial reorganisation
Opening
Time machine, BS events + macro context
Macro context
2020-Q2/Q3 COVID lockdown
2022 energy crisis
2023-2024 ECB rate hikes
Legend
Bankruptcy
Interim / reorg
KBO event
Credit advice
AI due-diligence brief
Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
Coming soon
AI-generated from Checked data; indicative, not legal or investment advice.
Company registry (CBE)
Activities
Adviesbureaus op het gebied van public relations en communicatie70210Activiteiten van adviesbureaus op het gebied van public relations en communicatie73300
Primary activity highlighted.
Names & trade names
| Legal nameFR | EF Pharma |
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.
Similar companies
R.D.V.
BE 0445.588.997 · Kortemark
POPLAR
BE 0430.913.392 · Brussel
ALKA
BE 0449.563.920 · Waterloo
DESMECHT
BE 0443.424.117 · Brussel
Ketchum
BE 0441.615.660 · Sint-Jans-Molenbeek